Yoshino, Tetsuhiro

写真a

Affiliation

School of Medicine, Joint Research Laboratory for precision Kampo pattern diagnosis (Shinanomachi)

Position

Project Senior Assistant Professor (Non-tenured)/Project Assistant Professor (Non-tenured)/Project Lecturer (Non-tenured)

External Links
Page Top ▲

Academic Background 【 Display / hide 】

  • 2002.04
    -
    2008.03

    Keio University, School of Medicine

    University, Graduated

Page Top ▲

Academic Degrees 【 Display / hide 】

  • 博士（医学）, Keio University, Dissertation, 2016.07

    The Difference between the Two Representative Kampo Formulas for Treating Dysmenorrhea: An Observational Study

Page Top ▲

Licenses and Qualifications 【 Display / hide 】

  • 医師免許, 2008.04

  • ECFMG certificate, 2021.09

  • 日本内科学会総合内科専門医, 2015.12

  • 日本東洋医学会漢方専門医, 2015.04

  • 日本内科学会認定医

display all >>

Page Top ▲
 

Research Areas 【 Display / hide 】

  • Life Science / General internal medicine

Page Top ▲
 

Books 【 Display / hide 】

Page Top ▲

Papers 【 Display / hide 】

  • Conference report: Fifth annual young researcher forum of the Japan Society of Medical and Pharmaceutical Sciences for Traditional Medicine

    Yoshino T., Tanide S., Hamai M., Nishiura R., Hatae A., Nose I., Oda Y., Fukada Y., Yang X., Ando H., Ogawa K., Murakami K., Nakashima S.

    Traditional and Kampo Medicine 12 ( 1 ) 74 - 79 2025.04

    　View Summary

    Seven young researchers presented their studies in the field of traditional Japanese herbal medicine (Wakan-yaku) at the Fifth Annual Young Researcher Forum held the day before the 2024 annual meeting of the Japan Society of Medical and Pharmaceutical Sciences for Traditional Medicine. Ms Tanide presented on the changes in flavonoid and synephrine content in chimpi based on the storage period. Ms Hamai discussed natural compounds that contribute to improving bortezomib resistance in myeloma cells and their mechanisms of action. Ms Nishiura presented the production of a monoclonal antibody against geniposide and its application in indirect competitive enzyme-linked immunosorbent assay. Mr Hatae presented about the effects of ninjin'yoeito on cisplatin-induced anorexia and the variations in intestinal clock genes. Ms Nose explored the analgesic effects of bushi-containing Kampo formulas, with a focus on goshajinkigan's improvement of cold allodynia. Dr Oda discussed the antifungal activity of henna leaves against Malassezia. Lastly, Mr Fukuda presented how cultivation environments affect the quality of Schizonepeta spikes, including their morphology and component content. The event, conducted both in person and online, attracted a total of 54 participants. Looking ahead, we aim to further develop and continue hosting this forum in 2025 and beyond, fostering the advancement of research in this field.

  • Survey of attitudes toward clinical research among Japanese traditional (Kampo) medicine specialists and certified doctors affiliated with the Japan Society for Oriental Medicine

    Nogami T., Uneda K., Yoshino T., Ito H., Imoto S., Tahara E., Sunagawa M., Takayama S., Yakubo S., Mitani K.

    Traditional and Kampo Medicine 12 ( 1 ) 27 - 37 2025.04

    　View Summary

    Aim: This study aims to assess the motivation, capability, and working environment of Japanese traditional (Kampo) medicine (JTM) specialists and certified physicians affiliated with the Japan Society for Oriental Medicine regarding clinical research. Their awareness and perception of COVID-19 studies and their interest in clinical research based on traditional JTM diagnostic concepts are explored. Methods: An online survey was conducted between May 20 and June 30, 2024, using Google Forms, targeting 2146 Japan Society for Oriental Medicine-certified JTM specialists and physicians. The survey covered their awareness of and participation in COVID-19 research, barriers to research, and educational needs for clinical researcher training. Results: In total, 570 participants (26.6%) responded, 44.1% of whom had more than 15 years of certification experience. Approximately 50% were unaware of the COVID-19 studies, and participation rates were low. The most common barriers to conducting clinical research included lack of time (58.1%), funding (54.8%), and research personnel (51.1%). In terms of educational needs, 74.3% of respondents expressed a need for statistical analysis training, and nearly 90% felt clinical research education should occur within 10 years of obtaining their medical licenses. Conclusion: This study reveals gaps in awareness and participation in clinical research among JTM specialists. Many respondents expressed willingness to engage in research; however, barriers such as limited time, funding, and personnel remain critical challenges. Furthermore, the need for specialized educational programs was strongly emphasized. Addressing these issues is essential for promoting clinical research in JTM.

  • A Simulated Interprofessional Team Conference Using Cross-Training for Junior Healthcare Students in Interprofessional Education: a Qualitative Content Analysis

    Tomisaki E., Haruta J., Horiguchi T., Arahata T., Fukui R., Uno S., Ando T., Yoshino T., Ishikawa S., Suzuki S., Yamaura K., Monkawa T.

    Advances in Medical Education and Practice 16   583 - 594 2025

    ISSN  1179-7258

    　View Summary

    Purpose: In 2021, we introduced a new simulation-based learning program focusing on a roleplay conference before patient discharge. This study aimed to evaluate the program’s effectiveness and highlight the significance of cross-training in interprofessional education (IPE). Methods: In September 2023, the program included 346 students (98 medical, 110 nursing, and 138 pharmacy students). The students’ reflective writing was analyzed using inductive content analysis to describe their learning and perspectives. The original items, subcategories, and main categories were extracted. The simulation involved the students role-playing various healthcare professionals during a discharge-planning conference for a stroke patient. This allowed them to experience the challenges and dynamics of interprofessional collaboration. Results: Student feedback emphasized the importance of understanding what constitutes a good healthcare team. A total of 203 items were grouped into eight main categories and 17 subcategories, including patient-centered care (related to the importance of patient-centered care, supporting patient decision-making, communicating with patients during conferences, and facilitating decision-making processes), contrasts in patient and interprofessional communication, conference communication (challenge of building consensus, the way to proceed conferences, importance of conference preparation, and process of information aggregation and realization of outcomes), mutual recognition and role contribution, building relationships (importance of daily interprofessional communication), understanding one’s profession (reflection on one’s own profession, understanding the roles of different professions, and communication within one’s own professional context), recursion into learning (motivation for continuous learning and improvement), and understanding other professions (understanding the role and perspectives of other professions and recognizing professional differences). Specific feedback highlighted improved empathy and communication skills. Students recognized the value of each profession’s contribution to patient care. Moreover, students reported a deeper appreciation of patient-centered approaches and the complexities of coordinating care across different healthcare roles. Conclusion: Simulated interprofessional team conferences using cross-training effectively taught junior students to understand the essence of a good healthcare team and the importance of a patient-centered approach. Cross-training significantly enhanced students’ interprofessional competencies, communication skills, and empathy toward other professions. This case underscores the necessity of incorporating cross-training into IPE to prepare healthcare professionals for collaborative practice and improve patient outcomes. Future research should consider expanding the scope to include more diverse scenarios and longitudinal assessments to measure longterm impacts on professional practice.

  • Three Kampo medicines—bofutsushosan, boiogito, and daisaikoto—have different effects on host fat accumulation and the intestinal microbiota in a high-fat-diet–induced mouse model of obesity

    Nakamichi K., Yoshino T., Akiyama M., Jibiki A., Yokoyama Y., Kawazoe H., Suzuki S., Watanabe K., Kim Y.G., Nakamura T.

    Journal of Natural Medicines  2025

    ISSN  13403443

    　View Summary

    Inhibiting body fat accumulation is important for the prevention of obesity. In Japan, three Kampo medicines are commonly used to treat obesity: bofutsushosan, boiogito, and daisaikoto. To compare the influences of these Kampo medicines on the intestinal microbiota, it is necessary to conduct a simultaneous investigation using the same mouse model under the same experimental conditions. C57BL/6J mice were divided into five groups: normal chow (NC), high-fat diet (HFD), HFD + 3% bofutsushosan extract (BTS), HFD + 3% boiogito extract (BOT), and HFD + 3% daisaikoto extract (DST). Epididymal white adipose tissue (WAT) weight, mesenteric WAT weight, serum triglyceride levels, and serum total cholesterol levels were measured. Additionally, total bacteria, alpha diversity, beta diversity, and bacterial composition in stool samples were measured. Body weight and epididymal WAT weight gain were significantly inhibited in the BTS-treated group and DST-treated group, but not in the BOT-treated group, compared with the HFD control group. Additionally, serum total cholesterol levels were significantly lower in the DST-treated group than in the HFD group. Specific intestinal bacteria, Clostridium sensu stricto 1, Erysipelatoclostridium, Roseburia, and the Lachnospiraceae NK4A136 group, were significantly changed in the Kampo-treated groups compared with the HFD group, and each of them was correlated with body weight gain, body fat rate, epididymal WAT weight, or mesenteric WAT weight. Our simultaneous investigation of BTS, BOT, and DST under the same conditions clearly demonstrated different changes in the intestinal microbiota and different effects on fat accumulation as well as their association among the three Kampo medicines.

  • 3-epi-18β-Glycyrrhetinic Acid or Its Glucuronide, the Metabolites of Glycyrrhizinic Acid with Individual Differences, Correlated with Diagnostic Marker for Licorice-Induced Pseudoaldosteronism in Humans

    Ryota Sakoda, Kan’ichiro Ishiuchi, Tetsuhiro Yoshino, Yuna Tsunoo, Takao Namiki, Keiko Ogawa-Ochiai, Kiyoshi Minamizawa, Koichi Fukunaga, Kenji Watanabe, Toshiaki Makino

    Drug Metabolism and Disposition 52 ( 12 ) 1407 - 1416 2024.12

    Accepted,  ISSN  00909556

    　View Summary

    Licorice is a crude drug that is used in traditional Japanese Kampo medicine and is also used as a sweetener. Occasionally, it causes pseudoaldosteronism (PsA) as a side effect. The major symptoms include hypokalemia, hypertension, edema, and low plasma aldosterone levels. PsA might be caused by the metabolites of glycyrrhizinic acid (GL), a component of licorice. The development of PsA markedly varies among individuals; however, the factors that cause these individual differences remain unknown. In this study, 78 patients who consumed Kampo medicines containing licorice were enrolled, and their laboratory data, including serum potassium levels, plasma aldosterone concentrations (PAC), and the concentrations of GL metabolites in the residual blood and/or urine samples were evaluated. Of the 78 participants, 18b-glycyrrhetinic acid (GA), 3-epi-GA, 3-oxo-GA, 18b-glycyrrhetinyl-30-O-glucuronide (GA30G), and 3-epi-GA30G were detected in the serum samples of 65, 47, 63, 62, and three participants, respectively. Of the 29 urine samples collected, GA30G and 3-epi-GA30G were detected in 27 and 19 samples. 3-epi-GA30G is a newly found GL metabolite. Moreover, 3-epi-GA, 3-oxo-GA, and 3-epi-GA30G were identified in human samples for the first time. High individual differences were found in the appearances of 3-epi-GA in serum and 3-epi-GA30G in urine, and the concentrations of these metabolites were correlated with serum PsA markers. The inhibitory titers of 3-epi-GA, 3-oxo-GA, GA30G, and 3-epi-GA30G on human 11b-hydroxysteroid dehydrogenase type 2 were almost similar. These findings suggest that 3-epi-GA and/or 3-epi-GA30G are associated with individual differences in the development of PsA.

display all >>

Page Top ▲

Papers, etc., Registered in KOARA 【 Display / hide 】

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

  • Aspirin for Thromboprophylaxis after a Fracture

    Yoshino T., Yamada Y., Tamura Y.

    New England Journal of Medicine 388 ( 16 ) e57 2023.04

    Rapid communication, short report, research note, etc. (scientific journal), Joint Work, Lead author, Corresponding author,  ISSN  0028-4793

  • 【生物活性天然物・擬天然物研究の最前線】最前線　甘草の副作用,偽アルドステロン症真の原因物質探索

    石内 勘一郎, 森永 紀, 吉野 鉄大

    ファルマシア ((公社)日本薬学会)  58 ( 12 ) 1130 - 1134 2022.12

    ISSN  0014-8601

  • Corrigendum: Identification of an alternative glycyrrhizin metabolite causing liquorice-induced pseudohyperaldosteronism and the development of ELISA system to detect the predictive biomarker (Front. Pharmacol., (2021), 12, 688508, 10.3389/fphar.2021.688508)

    Ishiuchi K., Morinaga O., Yoshino T., Mitamura M., Hirasawa A., Maki Y., Tashita Y., Kondo T., Ogawa K., Lian F., Ogawa-Ochiai K., Minamizawa K., Namiki T., Mimura M., Watanabe K., Makino T.

    Frontiers in Pharmacology 13   1090327 2022.11

    ISSN  1663-9812

    　View Summary

    In the published article, there was an error. The numbers of the concentrations were mistaken. A correction has been made to Results, Pharmacokinetics of GA metabolites in female and male EHBRs orally treated with GA, Paragraph 7. These sentences previously stated: “The concentrations of GA and its metabolites 12 h after oral administration of GA in female EHBRs were 3.2 μM of GA, 0.1 μM of 3MGA, 14 μM of 1, 4.3 μM of 2, 6.6 μM of 3, and 166 μM of 4.” and “The concentrations of GA and its metabolites 12 h after oral administration of GA in male EHBRs were 2.6 μM of GA, 1.2 μM of 3MGA, 102 μM of 1, 4.1 μM of 2, 1.2 μM of 3, and 198 μM of 4.” The corrected sentences appear below: “The concentrations of GA and its metabolites 12 h after oral administration of GA in female EHBRs were 2.7 μMof GA, 0.1 μM of 3MGA, 32 μM of 1, 10 μM of 2, 2.0 μMof 3, and 208 μMof 4.” and “The concentrations of GA and its metabolites 12 h after oral administration of GA in male EHBRs were 2.6 μM of GA, 1.6 μM of 3MGA, 177 μM of 1, 8.2 μM of 2, 2.2 μM of 3, and 237 μM of 4.” The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

  • Medicinal plant garden in Japan, the world, and the future “1st International Symposium on Kampo Medicine”

    Takahashi K., Mizukami H., Kuchta K., Yoshino T., Yamaoka D.

    Traditional and Kampo Medicine (Wiley)  9 ( 2 ) 136 - 137 2022.08

  • ヒトにおける甘草の副作用の発症を予測できる背景因子の探索

    迫田 凌太, 石内 勘一郎, 吉野 鉄大, 小川 恵子, 南澤 潔, 渡辺 賢治, 並木 隆雄, 牧野 利明

    和漢医薬学会学術大会要旨集 ((一社)和漢医薬学会)  39回   90 - 90 2022.08

display all >>

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • ヒト特有のグリチルリチン酸代謝産物の有用性とその個体差を決定する腸内細菌の同定

    2025.04
    -
    Present

    JSPS, 科研費基盤研究（Ｃ）, Research grant, Coinvestigator(s)

  • ICD-11伝統医学の病態－モジュールＩの活用と、安全で有効な漢方治療実践のための基盤整備研究

    2023.12
    -
    2025.03

    AMED, Commissioned ｒesearch, Coinvestigator(s)

  • 新機軸の鍼灸臨床研究モデル確立に向けた新規パラメータの検証

    2021.04
    -
    2022.03

    国立研究開発法人日本医療研究開発機構, 「統合医療」に係る医療の質向上・科学的根拠収集研究事業, 三村 將, Research grant, Coinvestigator(s)

    　View Summary

    本研究の目的は、鍼灸技法の重要な要素である筋硬結の触診情報(CORI-map)を、体表面の等高線情報に変換し、鍼灸効果のパラメータとして確立する事である。研究開発代表者の三村將は、精神神経科の主任教授として独創的な臨床研究を実施してきた実績があり、大学病院副院長として漢方医学センター長を兼任し、エビデンスレベルの低い伝承から医学的seedsを蒐集することに深い造詣を有する。本研究は研究開発代表者の包括的な指示とデータ評価の元、厳正な評価に耐える鍼灸研究の新たなパラメータ確立を実現する。現状では鍼灸治療で変化する体表等高線変化は施術者の感覚で捉えられているが、これを三次元画像技術によりデータ化し記録する。この記録データから鍼灸治療前後の変化差分を抽出し、パラメータとしての実用性を検証する。三次元画像技術は研究協力者の（株）スペースビジョンよりサポートを受け、側弯症診断装置に活用されているLED光源を使用した被検者背部の3次元(3D)撮影と、背部の対称性をモアレ様画像として視覚的に描出する技術を援用し、下記4期の計画を遂行する。■第1期(4月～6月) 計測機器の調整および計測準備：3DカメラのFocus位置決定、計測マーカの設置部位及び撮影画素及び撮影範囲を検討する。■第２期（７月～９月）コントロールデータ蒐集：健常者ボランティア20名を募集する。1回目の撮影後、治療相当時間(20分)安静臥位の後、2回目の撮影を行う。これら2画像データの差分解析を行う。■第3期(10月～12月)鍼灸治療効果観察データ集積：慶應義病院において観察研究として倫理委員会の承認を受けたプロトコールに則り、鍼灸外来の来院患者からボランティア40名を募集して通常診療に付帯して鍼灸治療前後のデータ取得を行う。■第4期(1月～3月)取得データの解析および評価：取得した3Dデータおよび差分解析が臨床医学的な意義を持ち得るか、将来的なビックデータ化に対応可能であるかについて多角的検討を加え、英文誌に論文投稿する。本研究の成果を起点とし、AMED統合医療に係る医療の質向上・科学的根拠収集研究事業に対し、新機軸のプロトコール作成研究・臨床研究を提案していく予定である。薬剤と併用する事で強力な効力を見込める鍼灸を、安心安全に利用可能な診療ツールとする戦略の第一歩である本研究の意義は、非常に大きい。

  • 甘草の副作用、偽アルドステロン症発症予防のためのバイオマーカーの開発

    2019.04
    -
    2020.03

    国立研究開発法人日本医療研究開発機構, 「統合医療」に係る医療の質向上・科学的根拠収集研究事業, 牧野 利明, Research grant, Coinvestigator(s)

    　View Summary

    １．グリチルリチン酸代謝産物の体内動態および11β-HSD2阻害メカニズムに関する研究
    GL代謝産物1-6が、血中、尿中に現れ、個体差の背景を明らかにし、偽アルドステロン症発症との関連について推定する。GLを飲ませたMrp2欠損ラットの尿から、まだ未知のGL代謝産物5と6の存在を示唆するデータを得ているので、それを単離同定する。GLからから1-6が生成される代謝酵素および体内動態に関わる肝臓および尿細管に発現するトランスポーターの各分子をヒトのタンパク質から同定し、各種多型の違いによる基質親和性の差を検討する。

    ２．グリチルリチン酸代謝産物の簡便定量法の開発
    現在、GL代謝産物はLC-MS/MSで測定しているが、それを簡便に検出するための酵素免疫法を用いた測定キットを開発し、一般病院・薬局でも副作用を予防するための検査を簡便に行えるようにする。

    ３．偽アルドステロン症を発症した患者の血中および尿中からのグリチルリチン酸代謝産物の探索
    実際に偽アルドステロン症を発症した患者の血清または尿からの血中および尿中3MGAおよび代謝産物1-6の分析を行う。現在、甘草を含む漢方薬を病院で処方する際には、偽アルドステロン症を発見するために血清カリウム値を定期的にモニターしながら行うことが多い。そこで、偽アルドステロン症を発症した患者と、発症しなかった患者において、検査時の残余血清および尿検体を用いて、それぞれのGL代謝産物の濃度をLC-MS/MSにより測定し、偽アルドステロン症の症状との相関関係、および副作用発症を予測するための濃度の閾値を求める。また、ラットでは現れないヒトにおける未知のGL代謝産物の存在が推測されているため、その同定も試みる。

    ４．偽アルドステロン症を発症した患者の血中からの発症と関連する内因性パラメーター探索
    さらに甘草を含む漢方薬を投与する前から偽アルドステロン症を発症しやすい患者背景が存在するかどうかを検証するため、3MGAおよびGL代謝産物1–6の体内の分布・排泄に影響しうる血中アルブミン濃度およびMrp2機能を反影する直接ビリルビン濃度などを測定し、偽アルドステロン症を発症した患者と発症しなかった患者における値の違いを検証する。

  • ICD-11での漢方医学分類の国際展開に向けた調査研究

    2017.04
    -
    2018.03

    厚生労働省, 厚生労働科学研究費補助金, 渡辺 賢治, Research grant, Coinvestigator(s)

    　View Summary

    本研究ではWHOに協力しながら日本漢方分類の特性を残した国際伝統医学分類の完成を目指すとともに、国際伝統医学分類に対するさまざまな意見を収集・分析することを目的とする。
    WHOの疾病及び関連保健問題の国際統計分類(国際疾病分類；ICD)は現在改訂作業中であり、2018年にICD-11としてWHO総会での承認を目指している。この改訂の中で国際伝統医学分類がICDの新しい章として組み入れられる計画である。2016年に専門家によるレビューを終了し、2017年に本格的なフィールドテストを行う計画である。先行して2016年にヨーロッパにおいてフィールドテストが施行されたが、国際伝統医学分類そのものに対する多様な意見が出された。意見の中には標準化ということに対する批判もあり、欧州での独自性を保ちたいという主張が論文として発表されている。こうした批判は日本漢方分類にも影響を及ぼしかねず、本研究では海外の主張を収集・分析することも行う。また、WHOの伝統医学分類の活動についての理解を国内外に向けて発信することも必要である。エビデンスとして示すために、実際の診療から漢方医学分類を分析し、国内外に発信していく必要がある。
    以上より、１）本研究ではWHO主導のフィールドテストへの協力と漢方医学分類への反映、２）コーディング・ガイドの作成、３）国際伝統医学分類に関する国内外の評価の収集ならびに分析、４）漢方分類のエビデンスの収集、５）WHO国際伝統医学分類への理解促進のためのシンポジウム開催、６）WHO-FIC 会議での報告ならびに情報交換を行う。
    本研究は日本漢方の特性を生かした国際伝統医学分類完成に向けた唯一かつ独創的な研究である。研究の一部で患者データを用いるが、既に倫理委員会の承認をもらっている研究の一部データを活用して、漢方医学分類のエビデンスとして呈示する。

display all >>

Page Top ▲

Awards 【 Display / hide 】

  • American college of physician Global physician Scholar

    Tetsuhiro Yoshino, 2025.04, American college of physician

    Type of Award： Award from international society, conference, symposium, etc.

  • 日本東洋医学会奨励賞

    吉野鉄大, 2024.06, 日本東洋医学会

    Type of Award： Award from Japanese society, conference, symposium, etc.

  • 2024年度ベストティーチャーアワード（4年生）

    吉野鉄大, 2025.07, 慶應義塾大学医学部

    Type of Award： Keio commendation etc.

  • 日本東洋医学雑誌ベストレビューワー

    吉野鉄大, 2022, 日本東洋医学会

    Type of Award： Honored in official journal of a scientific society, scientific journal

  • American college of physician Japan chapter academic award

    2021.06, American college of physician Japan chapter

    Type of Award： Award from international society, conference, symposium, etc.

display all >>

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • SYMPTOMATOLOGY

    2025

  • KAMPO MEDICINE

    2025

  • SYMPTOMATOLOGY

    2024

  • SYMPTOMATOLOGY

    2023

  • INTRODUCTION TO CLINICAL CLERKSHIPS

    2023

display all >>

Page Top ▲

Courses Previously Taught 【 Display / hide 】

  • KAMPO MEDICINE

    Keio University

    2025.04
    -
    2026.03

  • SYMPTOMATOLOGY

    Keio University

    2025.04
    -
    2026.03

  • SYMPTOMATOLOGY

    Keio University

    2024.04
    -
    2025.03

  • SYMPTOMATOLOGY

    Keio University

    2023.04
    -
    2024.03

  • INTRODUCTION TO CLINICAL CLERKSHIPS

    Keio University

    2023.04
    -
    2024.03

display all >>

Page Top ▲

Educational Activities and Special Notes 【 Display / hide 】

  • Post Clinical Clerkship-OSCE, Station Leader

    2018.04
    -
    Present

    , Special Affairs about A person who has work experience

  • KICKS

    2014.04
    -
    Present

    , Coaching of Students' Association

Page Top ▲
 

Memberships in Academic Societies 【 Display / hide 】

  • American college of physician, 

    2016
    -
    Present

  • The International Society for Traditional, Complementary, and Integrative Medicine Research, 

    2015.01
    -
    Present

  • 和漢医薬学会, 

    2014
    -
    Present

  • 日本東洋医学会, 

    2009.09
    -
    Present

  • 日本内科学会, 

    2008.11
    -
    Present
Page Top ▲

Committee Experiences 【 Display / hide 】

  • 2025.04
    -
    Present

    Associate editor, Academic consortium, Global Advances in Integrative Medicine & Health

  • 2025.03
    -
    Present

    The Topic Group on Traditional Medicine under Global Initiative on AI for Health Member, WHO

  • 2025.07
    -
    Present

    臨床研究推進委員会委員長, 日本東洋医学会

  • 2025.07
    -
    Present

    学術教育委員会委員, 日本東洋医学会

    　View Remarks

    学術教育委員会若手部会2024-

  • 2025.02

    Expert Consultation on Research Priorities in Traditional, Complementary, and Integrative Medicine Temporary Advisor, WHO WPRO

display all >>

Page Top ▲